ArticleCancers2022

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments.

Enzo M Scutigliani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.